Anzeige
Mehr »
Sonntag, 14.12.2025 - Börsentäglich über 12.000 News
News-Bombe: NurExone startet Human-Versuche vor FDA!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ3E | ISIN: US18507C1036 | Ticker-Symbol:
NASDAQ
12.12.25 | 21:59
12,720 US-Dollar
-1,93 % -0,250
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARPOINT NEURO INC Chart 1 Jahr
5-Tage-Chart
CLEARPOINT NEURO INC 5-Tage-Chart

Aktuelle News zur CLEARPOINT NEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.12.Here's What Boosted ClearPoint Neuro (CLPT) in Q31
20.11.ClearPoint Neuro completes acquisition of IRRAS Holdings1
20.11.ClearPoint Neuro, Inc.: ClearPoint Neuro Completes Acquisition of IRRAS568Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire...
► Artikel lesen
20.11.ClearPoint Neuro, Inc. - 8-K, Current Report-
CLEARPOINT NEURO Aktie jetzt für 0€ handeln
06.11.ClearPoint Neuro to acquire IRRAS Holdings in neurocritical care expansion3
06.11.ClearPoint Neuro, Inc.: ClearPoint Neuro Reports Third Quarter 2025 Results372Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire...
► Artikel lesen
06.11.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Agreement to Acquire IRRAS359Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment...
► Artikel lesen
06.11.ClearPoint Neuro, Inc. - 10-Q, Quarterly Report-
06.11.ClearPoint Neuro, Inc. - 8-K, Current Report1
05.11.ClearPoint Neuro, Inc.: ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025368SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation...
► Artikel lesen
07.10.ClearPoint Neuro reports positive results from brain tumor laser therapy study5
07.10.Hirntumor-Studie: Lasertherapie von ClearPoint Neuro zeigt vielversprechende Ergebnisse4
07.10.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles433SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation...
► Artikel lesen
06.10.ClearPoint Neuro expands regulatory approvals to 34 countries1
06.10.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide386The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCESS...
► Artikel lesen
06.10.CLPT Expands Into Robotic System Supporting Cell and Gene Therapies5
02.10.ClearPoint Neuro is developing a robotic neuro-navigation system for drug delivery2
01.10.ClearPoint Neuro developing robotic navigation system for brain surgeries1
01.10.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System422New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT)...
► Artikel lesen
25.09.ClearPoint Neuro appoints Dr. Paul Larson as chief medical officer2
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1